GlassScriptPhysician profile
Kayla Keiper
NPI 1114536893
$3,401.58
in general payments reported to CMS, 2019-2025
16 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $313 · 2024: $1,372 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.00 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.60 | 2023-2025 | |
| Alkermes, INC. | $565.39 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $384.67 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $273.00 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $220.90 | 2023-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $208.66 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $137.35 | 2024-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.97 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $99.74 | 2023-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $71.49 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $67.28 | 2024-2025 | Rexulti |
| Corium, LLC | $44.21 | 2023-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $34.37 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $30.57 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $13.38 | 2024 | Cobenfy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $13.00 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Keiper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.